VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
IRLA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
IRLAIRulya Therapeutics Inc.
$40.59$39M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
IRLA logo

IRulya Therapeutics Inc.

IRLA
NASDAQ · Rare Disease Biotech
$40.59
At close - Nov 18, 4:00 PM EST - USD
Market Cap$487M
P/E-4.6x
52W High$910.00
Volume118.6K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q1

Persistent Clinical Burn Masks Structural Liquidity Risks

Quince Therapeutics remains a high-risk, clinical-stage entity characterized by a total lack of revenue generation and persistent operational losses that have eroded equity to $15.7 million as of 2026Q1.

GrowthContracting
ProfitabilityNegative
ValuationReview
TechnicalsStrong
Explore valuation models
MARKET ACTION

IRLA price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

5/12 Beats

EPS beat 5 of last 12 quarters

02

Valuation risk

-113% Peers

P/E is 113% below peer median

03

Market leadership

RS 80 · Leader

High momentum (Outperforming 80% of market)

04

Strong Uptrend

Strong Trend

Price > 20DMA > 50DMA > 200DMA

Next CatalystEstimated earnings · Nov 14

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
IRLA-93.23%
S&P 500 (^GSPC)+6.88%
1-Year Return
IRLA-89.37%
S&P 500 (^GSPC)+10.62%
3-Year Return
IRLA-76.94%
S&P 500 (^GSPC)+75.83%
5-Year Return
IRLA-98.43%
S&P 500 (^GSPC)+73.35%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
-
Net income FY25
-$84M-47.8% YoY
Free cash flow FY25
-$42M-29.9% YoY
Operating margin FY25
-
ROIC (FY25)-482%
Avg ROIC 5Y-150.9%
ROE (TTM)-256.4%
Piotroski Score1 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate5/12 (50%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q3 2026Latest
Aug 14, 2026
-$12.31+56.1%
vs -$28.02
—
vs —
Q2 2026
May 12, 2026
$75.60+390.8%
vs -$26.00
—
vs —
Q2 2026
May 11, 2026
-$0.59+54.6%
vs -$1.30
—
vs —
Q2 2026
Apr 10, 2026
-$4.30-2292.9%
vs -$0.18
—
vs —
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Defense World·Oct 11, 2026
Quince Therapeutics (NASDAQ: QNCX) renames itself IRulya and sets IRLA ticker

What happened Quince Therapeutics, Inc. (NASDAQ: QNCX) said it changed its name to IRulya Therapeutics Inc. effective at 4:01 p.m. Eastern Time on October 9, 2026. The common stock is expected to begin trading on the Nasdaq Capital Market under IRLA on October 12, 2026. The filing says Brigette Roberts, M.D., became chief executive officer

GlobeNewsWire·Oct 9, 2026
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease

Company common stock to trade on Nasdaq under the symbol “IRLA” effective October 12, 2026 Key Management changes include new CEO, Brigette Roberts, M.D.; new CFO, John Militello, CPA; and new COO Keith R.

Defense World·Oct 7, 2026
Quince Therapeutics Stockholders Approve PIPE, Share Increase and Equity Plans

Quince Therapeutics (NASDAQ: QNCX) stockholders approved five proposals at the company's Oct. 6, 2026 special meeting, including measures related to the conversion of preferred stock, a private investment in public equity transaction, an increase in authorized common shares, and new equity compensation plans. Dirk Thye, Quince's Chief Executive Officer and Chief Medical Officer, called the virtual

Seeking Alpha·Oct 6, 2026
Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript

Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript

Filtered for IRulya Therapeutics Inc.More Headlines
04

Compare before deciding

Benchmark IRLA against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for IRulya Therapeutics Inc. (IRLA)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
IRLA logoIRLAIRulya Therapeutics Inc.Current
$40.59$487.27M-4.56——-256.45%—
RARE logoRAREUltragenyx Pharmaceutical Inc.
$17.73$1.75B-3.4520.13%-71.78%——
ACAD logoACADACADIA Pharmaceuticals Inc.
$17.83$3.05B8.6411.87%30.13%28.03%—
PTCT logoPTCTPTC Therapeutics, Inc.
$60.23$5B-47.44114.51%-9.17%——
KRYS logoKRYSKrystal Biotech, Inc.
$315.34$9.3B43.1933.94%47.91%17.02%—
RCKT logoRCKTRocket Pharmaceuticals, Inc.
$2.11$230.4M-14.85——-5.34%—

Compare IRLA vs Peers

IRulya Therapeutics Inc. (IRLA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs RARE

Most directly comparable listed peer for IRLA.

Scale Benchmark

vs IQV

Larger-name benchmark to compare IRLA against a more recognizable public peer.

Peer Set

Compare Top 5

vs RARE, ACAD, PTCT, KRYS

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

IRLA SEC Filings & Documents

IRulya Therapeutics Inc. (IRLA) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 13, 2026·SEC

Material company update

Oct 19, 2026·SEC

Material company update

Oct 9, 2026·SEC

10-K Annual Reports

2
FY 2026

Apr 10, 2026·SEC

FY 2025

Mar 24, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 13, 2026·SEC

FY 2026

Aug 14, 2026·SEC

FY 2026

May 11, 2026·SEC

Get notified when IRLA posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

IRLA Frequently Asked Questions

IRulya Therapeutics Inc. (IRLA) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
Is IRLA profitable?

No. IRulya Therapeutics Inc. (IRLA) reported a net loss of $106.8M over the trailing twelve months.

Dividend & Returns
What is IRLA's return on equity?

IRulya Therapeutics Inc. (IRLA) had a return on equity (ROE) of -256.4% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is IRulya Therapeutics Inc.'s free cash flow?

IRulya Therapeutics Inc. (IRLA) had negative free cash flow of $46.9M over the trailing twelve months.

What if you invested $1,000 in IRLA back in 2017?

Total return calculator · dividends reinvested · 9+ years of data

See returns →